Why did CHM.AX stock spike 25% today?

CHM.AX stock rose **25.00%** on 06 Feb 2026 after focused buying tied to clinical progress and sector comparisons. Low liquidity amplified the move; volume was **626,114** versus a **6,007,948** average, so one or few trades can shift price materially.

What is Meyka AI's view on CHM.AX stock?

Meyka AI rates CHM.AX with a score of **66.15 / B (HOLD)**. The grade weighs benchmark comparisons, sector metrics, growth and analyst signals. This is informational only and not financial advice.

What price target or forecast exists for CHM.AX stock?

Meyka AI's forecast model projects **A$0.0100** (quarterly target), implying **300.00%** upside from the current **AUD 0.0025**. Forecasts are model projections and not guaranteed.

What are the main risks for CHM.AX stock investors?

CHM.AX stock risks include negative EPS (**-0.01**), limited liquidity, funding needs, trial setbacks and historic dilution. The current ratio (**0.72**) signals possible short-term cash pressure.

AU Stocks

CHM.AX stock up 25% at ASX close 06 Feb 2026: small-cap biotech rally to monitor

ByHuzaifa Zahoor February 6, 2026February 6, 2026

CHM.AX stock led gains on the ASX at market close on 06 Feb 2026, rising 25.00% to A$0.0025 on unusually focused buying. Trading volume was 626,114 shares, below the 50-day average but enough to push the micro‑cap higher from an open of A$0.0020. Investors reacted to recent clinical updates and sector comparisons, sending Chimeric Therapeutics Limited (CHM.AX) into the top-gainers list in the Healthcare Biotechnology group. We break down why the move happened, what it means for valuation, and short-term risks ahead.